Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors

Next Previous
Trial Profile

AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Dendritic cell vaccines
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions
  • Acronyms AVERT

Most Recent Events

  • 31 May 2019 Results evaluating safety of nivolumab in combination with CMVpp65 mRNA pulsed DC vaccination, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
  • 31 May 2019 Status changed from active, no longer recruiting to discontinued as per results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
  • 07 Nov 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top